



Renal function and adverse clinical events in anticoagulated patients with atrial fibrillation: insights from the GLORIA-AF Registry Phase III

Yang Liu^{1,2} · Steven Ho Man Lam¹ · Giulio Francesco Romiti^{1,4} · Bi Huang^{1,3} · Yang Chen¹ · Tze Fan Chao^{5,6} · Brian Olshansky⁷ · Kui Hong^{2,8,9} · Menno V. Huisman¹⁰ · Gregory Y. H. Lip^{1,11} .
on behalf of the GLORIA-AF Investigators

Accepted: 2 January 2025 / Published online: 9 February 2025
© The Author(s) 2025

Abstract

Renal function, assessed by creatinine clearance (CrCl), affects the efficacy and safety of oral anticoagulant (OAC) therapy in patients with atrial fibrillation (AF). To investigate the association between CrCl and the risk of clinical adverse events and compare the safety profiles of vitamin K antagonists (VKA) and non-vitamin K antagonist oral anticoagulants (NOAC). Patients with newly diagnosed AF (<3 months before baseline visit) were collected from the prospective Global Registry on Long-Term Oral Anti-Thrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry Phase III. Clinical events assessed included the composite outcome (all-cause death, thromboembolism, and major bleeding), cardiovascular (CV) death, myocardial infarction (MI), and other single outcomes. 10,594 AF patients (mean age 70.35 ± 9.92 years; 55% male; 73% on NOAC) were included. Increasing CrCl was associated with decreased risks of all cause death, composite outcomes and CV-death with in patients with $\text{CrCl} < 80$ mL/min. Multivariate Cox models indicated that compared to VKA, NOAC was associated with lower risks of all cause death (adjusted hazard ratio [aHR] 0.68, 95% CI 0.58–0.78), composite outcomes (aHR 0.77, 95% CI 0.69–0.86), CV-death (aHR 0.70, 95% CI 0.56–0.87), and major bleeding (aHR 0.74, 95% CI 0.61–0.91) in AF patients. For $\text{CrCl} < 30$ mL/min, lower risks of all-cause death, composite outcomes and CV death were related to NOAC therapy. In this large prospective global registry, NOACs were associated with better outcomes compared with VKA for patients with normal or impaired renal function.

Menno V. Huisman and Gregory Y. H. Lip are co-chairs of the GLORIA-AF Registry programme.

✉ Gregory Y. H. Lip
gregory.lip@liverpool.ac.uk

¹ Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK

² Department of Cardiovascular Medicine, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China

³ Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

⁴ Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy

⁵ Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

⁶ Institute of Clinical Medicine, and Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan

⁷ Division of Cardiology, The University of Iowa, Iowa City, IA, USA

⁸ Department of Genetic Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China

⁹ Jiangxi Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China


¹⁰ Department of Medicine – Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands

¹¹ Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

Graphical abstract

Renal Function and Adverse Clinical Events in Anticoagulated Patients with Atrial Fibrillation: Insights from the GLORIA-AF Registry Phase III

Atrial fibrillation (AF) patients with oral anticoagulation (OAC) collected from GLORIA-AF Registry Phase III




N = 10,594

- Oral anticoagulation NOAC vs. VKA
- Renal Function
 - CrCl (mL/min)
 - < 95
 - 80 – 95
 - 50 – 80
 - 30 – 50
 - < 30
- Safety and Efficacy
 - All-cause death
 - Thromboembolism
 - Major bleeding

CrCl: creatinine clearance

Composite outcomes included all-cause death, major bleeding and thromboembolisms.



For patients with CrCl < 80 mL/min, increasing CrCl is associated with a decreased risk of composite outcomes.

Renal function	No. event		aHR (95% CI)	P for interaction
	VKA	NOAC		
Overall	439	876	0.77 (0.68, 0.86)	0.642
CrCl > 95	72	165	0.68 (0.51, 0.91)	
CrCl 80 to < 95	48	115	0.85 (0.60, 1.19)	
CrCl 50 to < 80	160	369	0.87 (0.72, 1.06)	
CrCl 30 to < 50	108	197	0.81 (0.64, 1.04)	
CrCl < 30	51	30	0.56 (0.35, 0.89)	

Compared with VKA, patients receiving NOAC have lower risks of composite outcomes.

Keywords Atrial fibrillation · Oral anticoagulant · Vitamin K antagonists (VKA) · Non-vitamin K antagonist oral anticoagulants (NOACs) · Renal function

Introduction

Atrial fibrillation (AF) significantly increases the risk of stroke, leading to a substantial and growing burden on modern healthcare services [1]. To reduce stroke risk, the non-vitamin K antagonist oral anticoagulants (NOACs) have emerged as the preferred choice compared to the vitamin K antagonists (VKA), especially for patients newly initiating anticoagulation therapy [2].

NOACs exhibit varying degrees of renal dependency for excretion, making the assessment of renal function essential for determining appropriate dosing in line with guidelines [3, 4], typically using the Cockcroft-Gault formula to estimate creatinine clearance (CrCl) [5]. In patients with AF, chronic kidney disease (CKD) is independently associated with increased major bleeding and all-cause mortality [6, 7]. Consequently, considerable attention has been directed toward the safety of OAC therapy across varying renal functions, which includes ensuring appropriate dosing,

evaluating drug persistence, and monitoring renal function changes over time to guide clinical prescribing decisions effectively [8]. Rather than retrospective monocentre data, more prospective global multicentre data on renal function in anticoagulated patients are needed.

The Global Registry on Long-Term Oral Anti-Thrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry is a multicentre observational study enrolling up to 56,000 newly diagnosed nonvalvular AF patients in nearly 50 countries [9]. We assessed the effect of renal function on the occurrence of clinical adverse events by comparing NOAC and VKA treatment, in this prospective global registry.

Methods

Study population

GLORIA-AF included patients with newly diagnosed atrial fibrillation (<3 months before baseline visit). The study design has been previously reported [10]. During phase III (January 2014–December 2016), patients with or without OAC prescriptions were recruited with 3-year follow-up with scheduled visits at 6, 12, 24 and 36 months. Recruited patients were treated based on local clinical practice, with treatment choices determined by treating physicians. During follow-up, all major events, concomitant disease, and treatment were recorded.

At baseline, the following data were collected: age, sex, race, body mass index (BMI), smoking and drinking status, type of AF (paroxysmal, persistent, permanent), CHA₂DS₂-VASc score, comorbidities (hypertension, diabetes, hyperlipidemia, chronic artery disease, congestive heart failure, Transient Ischemic Attack (TIA), peripheral artery disease, chronic obstructive pulmonary disease), and history of clinical events (history of thromboembolism, stroke, bleeding), OAC therapy and antiplatelet therapy. Patients with missing renal function (serum creatinine), OAC therapy and clinical outcomes were excluded.

Renal function estimation and classification

Creatinine clearance, used to estimate renal function, was calculated according to Cockcroft-Gault in males: $\text{CrCl (mL/min)} = (140 - \text{age}) * \text{weight (kg)} / 72 * \text{serum creatinine} (*0.85 \text{ if females})$ [11]. The population was divided into five groups by baseline CrCl: >95, 80 to <95, 50 to <80, 30 to <50, <30 mL/min. To explore the relationships between OAC therapy and renal function, patients were then sub-grouped by OAC treatment, including NOAC versus VKA, or individual

NOAC (apixaban, rivaroxaban, dabigatran, edoxaban) versus VKA.

Clinical adverse events and endpoints

Myocardial infarction (MI) was defined as the development of significant Q-waves in at least 2 adjacent electrocardiogram leads or met criteria reported in previous study [12]. Major bleeding was defined according to the International Society of Thrombosis and Haemostasis classification [13]. Stroke was described as an acute onset of a focal neurological deficit of presumed vascular origin lasting for ≥ 24 h, or resulting in death, including ischemic stroke, haemorrhagic stroke, and uncertain classification strokes. Thromboembolism (TE) was defined as a composite of ischemic stroke, transient ischemic attack, and non-central-nervous-system atrial embolism.

We examined clinical endpoints including a composite outcomes, defined as ‘all-cause death, TE and major bleeding’. We also examined individual outcomes including all-cause death, major bleeding, cardiovascular (CV) death, MI, stroke and TE.

Statistical analysis

Continuous variables were represented by the mean (\pm standard deviation (SD)) and were compared by student’s t-test while categorical variables were represented by frequencies and percentages (n (%)) and were compared by Pearson’s Chi-squared test. The cumulative events between NOAC and VKA were compared using the Chi-squared test across various levels of renal function, respectively.

Multivariable Cox proportional hazard model was applied to compare the association between the adverse outcomes and OAC treatment at different levels of CrCl. Hazard ratio (HR) and 95% confidence intervals (CI) were calculated for indicators by comparing the VKA group and NOAC group in five levels of CrCl, respectively, and shown by table and forest plot. Restricted cubic spline (RCS) curves were used to explore the nonlinear relationship between CrCl and adverse clinical events and this relationship was compared between VKA and NOAC treatment [14]. Reasonable knots were selected according to the Akaike Information Criterion (AIC). The knots in outcomes of all-cause death, composite outcomes, CV death, major bleeding, MI, and stroke were set as 3, and TE was set as 4. Reference was set as CrCl=80 mL/min.

Interaction analyses were used to assess if the association between renal function and various clinical outcomes are modified by (1) different OAC treatments; and (2) different ethnic groups (Asian/non-Asian). Multivariable models were adjusted by age, sex, race, BMI, smoking and drinking

status, comorbidities (coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease, peripheral artery disease, diabetes, hypertension), prior TE, previous bleeding, and any antiplatelet drug use.

The statistical analysis for this study was conducted using R (version 4.3.1, R Core Team 2020, Vienna, Austria). Results with $P < 0.05$ were deemed to be statistically significant.

Results

Baseline characteristics

A total of 10,594 patients with AF (age 70.35 ± 9.92 years, 55% males, 56% paroxysmal AF) were included and divided into five groups by CrCl: ≥ 95 , 80 to <95 , 50 to <80 , 30 to <50 and <30 mL/min (Table 1). Overall, 2,797 (26%) patients received apixaban, 2,273 (21%) dabigatran, and 2,485 (23%) rivaroxaban.

Patients with CrCl 30 to <50 mL/min were the oldest (79.22 ± 6.21 years) while patients with CrCl >95 mL/min had the highest mean BMI (33.12 ± 6.60 kg/m²). For patients with CrCl <30 mL/min, 51% received VKA and 28% received apixaban, with the latter having the highest CHA₂DS₂-VASc score (4.33 ± 1.46).

3-year cumulative incidence of clinical adverse results

After three years of follow-up, NOAC users had lower cumulative incidence rates of all-cause death (6.48% vs. 10.35%, $P < 0.01$), composite outcomes (11.33% vs. 15.36%, $P < 0.001$), CV death (2.82% vs. 4.55%, $P < 0.001$), and major bleeding (3.70% vs. 5.07%, $P = 0.001$) compared with VKA therapy (Table 2).

For patients with CrCl >95 mL/min, participants receiving NOAC had a lower cumulative incidence of all-cause death (3.40% vs. 5.79%, $P = 0.004$), composite outcomes (7.11% vs. 9.93%, $P = 0.013$) and major bleeding (2.54% vs. 4.28%, $P = 0.016$). For patients with CrCl <30 mL/min, patients prescribed NOAC had a lower cumulative incidence rate of all-cause death (20.37% vs. 39.47%, $P = 0.002$), composite outcomes (27.78% vs. 44.74%, $P = 0.009$) and CV death (10.19% vs. 22.81%, $P = 0.012$).

Multivariable nonlinear analysis and RCS curves for renal function

After adjustment, the estimated RCS curve suggested nonlinear associations in outcomes of all-cause death, composite outcomes, and CV death in VKA and NOAC groups with

an ‘L-shaped’ curve. For patients with CrCl <80 mL/min, the risk of all-cause death, composite outcomes and CV death declined with increasing CrCl in patients with VKA/NOAC therapy. For patients with CrCl >80 mL/min, those prescribed NOAC had lower risk of major bleeding compared to those prescribed a VKA (Fig. 1).

Univariable and multivariable analysis for OAC type

Figure 2 shows the forest plot of the Cox regression analysis. Considering all AF patients, those prescribed NOAC had lower risk of all-cause death (HR 0.62, 95% CI 0.54–0.71), composite outcomes (HR 0.72, 95% CI 0.65–0.81), CV death (HR 0.62, 95% CI 0.50–0.76) and major bleeding (HR 0.72, 95% CI 0.59–0.88) compared to those prescribed VKA.

Patients prescribed with NOAC consistently had lower risk of all-cause death at every CrCl groups. For those with CrCl <30 mL/min, NOAC prescription was associated with lower risk of all-cause death (HR: 0.48, 95% CI: 0.29–0.80), composite outcomes (HR 0.58, 95% CI 0.37–0.90), CV death (HR: 0.42, 95% CI: 0.21–0.85). After adjustment for age, sex, BMI, smoking/drinking status, comorbidities and pharmacotherapies, similar results were found in patients with CrCl >95 mL/min and CrCl <30 mL/min.

Individual NOACs versus VKA

Comparisons of individual OAC drugs are shown in Table 3. Given the small number of patients prescribed edoxaban (CrCl at all levels) and dabigatran (CrCl <30 mL/min), these data were not analysed. Compared to a VKA, apixaban and dabigatran were associated with a decreased risk of all-cause death (HR: 0.69, 95% CI: 0.57–0.82) (HR: 0.63, 95% CI: 0.51–0.78) and composite outcomes (HR: 0.79, 95% CI: 0.68–0.91) (HR: 0.70, 95% CI: 0.60–0.83).

Compared to a VKA, apixaban was consistently associated with a decreased risk of all-cause death in patients with CrCl = 30–50 and <30 mL/min. Dabigatran was associated with a lower risk of all cause death in patients with CrCl >95 and 30–50 mL/min. Rivaroxaban was associated with decreased risk of all-cause death, composite outcomes, and major bleeding in patients with CrCl >95 mL/min.

Age subgroups

The baseline table suggested that patients with lower renal function were older, and were more likely to receive VKA. Therefore, we explored the impact of age on outcomes with NOAC versus VKA. Supplementary Fig. 1 shows the age subgroup of association between outcomes and NOAC versus VKA. Patients receiving NOAC were associated with a

Table 1 Baseline characteristic of patients with atrial fibrillation in different levels of creatinine clearance

Characteristic	Overall N=10,594	CrCl≥95 mL/min N=3,046	CrCl 80 to <95 mL/min N=1,730	CrCl 50 to <80 mL/min N=4,224	CrCl 30 to <50 mL/min N=1,372	CrCl<30 mL/min N=222
Anticoagulation therapy						
VKA	2,859 (27%)	725 (24%)	452 (26%)	1,147 (27%)	421 (31%)	114 (51%)
Apixaban	2,797 (26%)	807 (26%)	440 (25%)	1,061 (25%)	427 (31%)	62 (28%)
Dabigatran	2,273 (21%)	635 (21%)	420 (24%)	981 (23%)	216 (16%)	21 (9.5%)
Rivaroxaban	2,485 (23%)	839 (28%)	386 (22%)	948 (22%)	287 (21%)	25 (11%)
Edoxaban	180 (1.7%)	40 (1.3%)	32 (1.8%)	87 (2.1%)	21 (1.5%)	0 (0%)
Age, years old						
Mean (SD)	70.35 (9.92)	62.50 (9.42)	68.80 (8.01)	73.36 (7.53)	79.22 (6.21)	78.20 (8.81)
Median (25%, 75%)	71.00 (65.00,77.00)	64.00 (57.00,69.00)	69.00 (64.00,74.00)	74.00 (69.00,79.00)	80.00 (75.00,84.00)	81.00 (74.00,85.00)
Sex, n (%)						
Male	5,783 (55%)	2,048 (67%)	990 (57%)	2,152 (51%)	495 (36%)	98 (44%)
Female	4,811 (45%)	998 (33%)	740 (43%)	2,072 (49%)	877 (64%)	124 (56%)
Race, n (%)						
White	8,496 (80%)	2,605 (86%)	1,379 (80%)	3,277 (78%)	1,060 (77%)	175 (79%)
Arab or Middle East	19 (0.2%)	10 (0.3%)	1 (<0.1%)	6 (0.1%)	2 (0.1%)	0 (0%)
Asian	1,641 (15%)	300 (9.8%)	277 (16%)	787 (19%)	248 (18%)	29 (13%)
Black or Afro-Caribbean	180 (1.7%)	77 (2.5%)	31 (1.8%)	42 (1.0%)	20 (1.5%)	10 (4.5%)
Others	258 (2.4%)	54 (1.8%)	42 (2.4%)	112 (2.7%)	42 (3.1%)	8 (3.6%)
BMI, kg/m²						
Mean (SD)	28.92 (6.02)	33.12 (6.60)	29.18 (5.02)	27.02 (4.53)	25.58 (4.58)	26.01 (5.53)
Median (25%, 75%)	27.80 (24.80,32.00)	32.10 (28.20,37.10)	28.35 (25.73,31.90)	26.40 (24.00,29.40)	25.00 (22.50,28.10)	25.40 (22.30,28.30)
Smoking status, n (%)						
Never smoked	6,043 (57%)	1,476 (48%)	983 (57%)	2,554 (60%)	896 (65%)	134 (60%)
Ex-smoker	3,549 (34%)	1,129 (37%)	589 (34%)	1,347 (32%)	407 (30%)	77 (35%)
Current smoker	1,002 (9.5%)	441 (14%)	158 (9.1%)	323 (7.6%)	69 (5.0%)	11 (5.0%)
Alcohol status, n (%)						
No alcohol	4,525 (43%)	1,029 (34%)	672 (39%)	1,934 (46%)	766 (56%)	124 (56%)
<1 drink/week	2,808 (27%)	870 (29%)	457 (26%)	1,080 (26%)	337 (25%)	64 (29%)
1–7 drinks/week	2,442 (23%)	820 (27%)	431 (25%)	941 (22%)	219 (16%)	31 (14%)
≥8 drinks/week	819 (7.7%)	327 (11%)	170 (9.8%)	269 (6.4%)	50 (3.6%)	3 (1.4%)
Type of AF, n (%)						
Paroxysmal AF	5,894 (56%)	1,660 (54%)	991 (57%)	2,349 (56%)	766 (56%)	128 (58%)
Persistent AF	3,712 (35%)	1,161 (38%)	586 (34%)	1,458 (35%)	440 (32%)	67 (30%)
Permanent AF	988 (9.3%)	225 (7.4%)	153 (8.8%)	417 (9.9%)	166 (12%)	27 (12%)
CHA₂DS₂-VAsC score						
Mean (SD)	3.20 (1.48)	2.47 (1.25)	2.90 (1.36)	3.44 (1.39)	4.31 (1.35)	4.33 (1.46)
Medians (25%, 75%)	3.00 (2.00, 4.00)	2.00 (1.00, 3.00)	3.00 (2.00, 4.00)	3.00 (2.00, 4.00)	4.00 (3.00, 5.00)	4.00 (3.00, 5.00)
Comorbidities, n (%)						
Hypertension	8,083 (76%)	2,395 (79%)	1,293 (75%)	3,111 (74%)	1,093 (80%)	191 (86%)
Diabetes	2,542 (24%)	915 (30%)	364 (21%)	833 (20%)	358 (26%)	72 (32%)
Hyperlipidemia	4,519 (43%)	1,301 (43%)	734 (42%)	1,754 (42%)	609 (44%)	121 (55%)
Chronic artery disease	1,887 (18%)	458 (15%)	293 (17%)	771 (18%)	299 (22%)	66 (30%)
Congestive heart failure	2,337 (22%)	646 (21%)	342 (20%)	861 (20%)	409 (30%)	79 (36%)
Thromboembolism	1,579 (15%)	325 (11%)	225 (13%)	715 (17%)	272 (20%)	42 (19%)
Stroke	1,125 (11%)	236 (7.7%)	157 (9.1%)	498 (12%)	199 (15%)	35 (16%)
TIA	505 (4.8%)	109 (3.6%)	77 (4.5%)	223 (5.3%)	89 (6.5%)	7 (3.2%)
Previous bleeding	574 (5.4%)	121 (4.0%)	82 (4.7%)	256 (6.1%)	95 (6.9%)	20 (9.0%)
Peripheral artery disease	305 (2.9%)	67 (2.2%)	35 (2.0%)	126 (3.0%)	61 (4.4%)	16 (7.2%)
COPD	696 (6.6%)	181 (5.9%)	114 (6.6%)	253 (6.0%)	124 (9.0%)	24 (11%)
Antiplatelet drug use, n (%)	1,940 (18%)	561 (18%)	296 (17%)	758 (18%)	271 (20%)	54 (24%)

Table 1 (continued)

Characteristic	Overall N=10,594	CrCl \geq 95 mL/min N=3,046	CrCl 80 to <95 mL/ min N=1,730	CrCl 50 to <80 mL/min N=4,224	CrCl 30 to <50 mL/min N=1,372	CrCl <30 mL/min N=222
Chronic dialysis, n (%)	27 (0.3%)	0 (0%)	0 (0%)	0 (0%)	2 (0.1%)	25 (11%)
Renal transplantation, n (%)	15 (0.1%)	1 (<0.1%)	1 (<0.1%)	3 (<0.1%)	7 (0.5%)	3 (1.4%)

Continuous variables were presented by Mean (SD) and Median (IQR). Catalogue variables were presented by frequency and percentage(n%) CrCl, creatinine clearance (mL/min); BMI: body mass index, OAC: oral anticoagulation, VKA: Vitamin K antagonists, SD: standard deviation, IQR: interquartile range, ACE-I: angiotensin-converting enzyme inhibitors, ARB: angiotensin II receptor blockers, TIA: Transient ischemic attack, COPD: chronic obstructive pulmonary disease

lower risk of major bleeding in patients with age \geq 75 (HR: 0.60, 95% CI: 0.46–0.80, $P_{\text{interaction}} = 0.042$). No significant interaction was noted between age groups and OAC use in other outcomes (All $P_{\text{interaction}} > 0.05$).

Association between Asian/Non-Asian individuals and clinical events

Previous studies have shown that Asian patients are prescribed NOAC less frequently [15] and have a higher risk of bleeding [16]. In our baseline, we observed significant heterogeneity in renal function among Asian patients. Therefore, we performed the analysis to assess the outcome risks in Asian patients with varying renal functions (Supplementary Fig. 2). Non-Asian individuals were associated with higher risk of all-cause death (HR: 1.51, 95% CI: 1.17–1.93), composite outcomes (HR: 1.38, 95% CI: 1.15–1.66), and major bleeding (HR: 1.46, 95% CI: 1.05–2.03). No significant interaction was noted between ethnic groups and renal function (All $P_{\text{interaction}} > 0.05$).

Discussion

We analysed the impact of renal function, measured by CrCl, on major clinical events in patients prescribed VKAs and NOACs. Our finding indicated that increasing CrCl was associated with decreased risk of all-cause death, composite outcomes, and CV death among patients with CrCl < 80 mL/min. Furthermore, NOAC use was independently correlated with a lower risk of all-cause death, composite outcomes, CV death, and major bleeding compared to VKA. Additionally, NOACs were consistently associated with decreased risk of all-cause death and composite outcomes across different levels of renal function (with a more pronounced effect in patients with CrCl > 95 and < 30 mL/min). No significant interaction was observed between OAC therapy and renal function on all-cause death. These results reinforce the importance of evaluating renal function when prescribing anticoagulants and highlight the benefits of NOAC in patients with diverse renal profiles.

Worsening CrCl has been identified as an independent predictor of ischemic stroke, systemic embolism, and bleeding in patients with AF [17]. In the ROCKET AF subgroup analysis, CrCl was analyzed as a continuous variable, revealing that the HR of all stroke and systemic embolism risk increased by 12% for every 10 mL/min decline in renal function (HR, 1.12; 95% CI, 1.07–1.16), irrespective of OAC use [18]. In contrast, our study found no significant association between decreasing CrCl and the risk of stroke, likely because our cohort included only patients receiving OACs (with 70% oarticipants receiving NOACs).

For patients with AF and stage 3 CKD who are at elevated risk of stroke, warfarin, direct thrombin or factor Xa inhibitors are the recommended treatment options. For those with stage 4 CKD, treatment with warfarin or labelled doses of NOAC is also considered reasonable (class 2a recommendation) to reduce the risk of stroke [3]. When prescribing OACs for CKD patients, it is essential to carefully balance the risk of thromboembolism against the risk of bleeding [19], particularly in the Asian population who may have an evaluated bleeding risks [16]. Indeed, CKD patients with AF often present with clinical complexities, including a high prevalence of frailty, multimorbidity and polypharmacy, which underscores the need for a more holistic and individualized treatment approach [20, 21].

Consistent with our study, the ARISTOTLE trial demonstrated that apixaban significantly reduced the risk of major bleeding compared to VKA, but with a decreasing trend among patients with a CrCl of 25–50 mL/min [22]. In contrast, the ORBIT AF study showed no interaction between OAC therapy and CKD concerning the risk of all-cause mortality and CV death after adjusting for covariates [23].

For patients with severe renal dysfunction, the present study demonstrated NOAC prescription was associated with reduced risks of all-cause death, and CV death, but not with the risk of major bleeding. Dabigatran significantly reduced the risk of CV death and major bleeding, and the same reductions were observed for apixaban, but not for rivaroxaban in patients with CrCl 30 to < 50 mL/min.

Previous studies demonstrated similar findings. Coccheri et al. found that dabigatran was better than VKA for avoiding major bleeding; the number needed to treat (NNT) was

Table 2 Three-year cumulative incidence rate of different clinical adverse events in two different OACs cohorts (VKA or NOAC therapy) and 5 levels of renal function

Outcomes	Population divided by CrCl (mL/min)	VKA, <i>n</i> (3-year cumulative incidence rate%)	NOAC, <i>n</i> (3-year cumulative incidence rate%)	<i>P</i> value
All cause death	Overall	296 (10.35%)	501 (6.48%)	<0.001
	>95	42 (5.79%)	79 (3.40%)	0.004
	80 to <95	31 (6.86%)	63 (4.93%)	0.12
	50 to <80	97 (8.46%)	197 (6.40%)	0.020
	30 to <50	81 (19.24%)	140 (14.72%)	0.036
	<30	45 (39.47%)	22 (20.37%)	0.002
Composite outcomes	Overall	439 (15.36%)	876 (11.33%)	<0.001
	>95	72 (9.93%)	165 (7.11%)	0.013
	80 to <95	48 (10.62%)	115 (9.00%)	0.3
	50 to <80	160 (13.95%)	369 (11.99%)	0.087
	30 to <50	108 (25.65%)	197 (20.72%)	0.042
	<30	51 (44.74%)	30 (27.78%)	0.009
Cardiovascular death	Overall	130 (4.55%)	218 (2.82%)	<0.001
	>95	12 (1.66%)	33 (1.42%)	0.6
	80 to <95	17 (3.76%)	27 (2.11%)	0.056
	50 to <80	37 (3.23%)	80 (2.60%)	0.3
	30 to <50	38 (9.03%)	67 (7.05%)	0.2
	<30	26 (22.81%)	11 (10.19%)	0.012
Major bleeding	Overall	145 (5.07%)	286 (3.70%)	0.001
	>95	31 (4.28%)	59 (2.54%)	0.016
	80 to <95	14 (3.10%)	44 (3.44%)	0.7
	50 to <80	55 (4.80%)	127 (4.13%)	0.3
	30 to <50	33 (7.84%)	45 (4.73%)	0.022
	<30	12 (10.53%)	11 (10.19%)	>0.9
Myocardial infarction	Overall	53 (1.85%)	145 (1.87%)	>0.9
	>95	10 (1.38%)	28 (1.21%)	0.7
	80 to <95	5 (1.11%)	19 (1.49%)	0.6
	50 to <80	19 (1.66%)	63 (2.05%)	0.4
	30 to <50	15 (3.56%)	30 (3.15%)	0.7
	<30	4 (3.51%)	5 (4.63%)	0.7
Stroke	Overall	78 (2.73%)	190 (2.46%)	0.4
	>95	15 (2.07%)	41 (1.77%)	0.6
	80 to <95	10 (2.21%)	21 (1.64%)	0.4
	50 to <80	32 (2.79%)	84 (2.73%)	>0.9
	30 to <50	15 (3.56%)	39 (4.10%)	0.6
	<30	6 (5.26%)	5 (4.63%)	0.8
TE	Overall	81 (2.83%)	216 (2.79%)	>0.9
	>95	15 (2.07%)	44 (1.90%)	0.8
	80 to <95	11 (2.43%)	28 (2.19%)	0.8
	50 to <80	31 (2.70%)	94 (3.05%)	0.5
	30 to <50	16 (3.80%)	44 (4.63%)	0.5
	<30	8 (7.02%)	6 (5.56%)	0.7

CrCl, creatinine clearance; TE, thromboembolism

lower in patients treated with dabigatran than with VKA. Data concerning apixaban, and rivaroxaban showed higher NNT [24]. Dabigatran is generally not recommended for use in patients with CrCl < 30 mL/min, although our study showed a small number of AF patients with CrCl < 30 mL/min used dabigatran. In patients with severe CKD, our data indicated that apixaban prescription was associated with better safety versus VKA, but other NOACs were not associated with better safety. Apixaban is less dependent on

renal excretion compared with other NOACs, which could explain its superior safety benefit [25]. A meta-analysis indicated that compared to dabigatran, apixaban was associated with less major bleeding in patients with moderate renal impairment (CrCl 25–49 mL/min) [26] which is consistent with our result in patients with moderate renal impairment (CrCl 30 to < 50 mL/min). Also, previous studies demonstrated a slower decline in renal function in patients taking NOAC compared with warfarin [27].




Fig. 1 Restrictive cubic spline curve. VKA, vitamin K anticoagulant; Ref., reference; NOACs, Non-vitamin K antagonist oral anticoagulants

Patients with high CrCl (>95 mL/min) were more likely to benefit from NOACs compared to VKAs, particularly regarding the risks of all-cause death, major bleeding, and the composite outcome. Dabigatran, apixaban and rivaroxaban demonstrated similar risks of clinical outcomes. Similarly, Korean nationwide data showed that dabigatran, apixaban, and rivaroxaban were safer than warfarin in AF patients with CrCl > 95 mL/min [28]. Korean cohort data also showed that edoxaban was associated with a decreased risk of major bleeding and mortality during a median follow-up period of 5 months [29]. A US *post-hoc* analysis showed that among patients with CrCl > 80 mL/min, the risks of stroke and bleeding rates were similar among warfarin users and dabigatran users, but the risk of first ischemic stroke was lower in dabigatran users (HR 0.84), and the risk was higher in rivaroxaban user and apixaban user compared to warfarin users (HRs 1.07 and 1.35, respectively) [30]. On the other hand, in patients with CrCl > 80 mL/min from the ROCKET-AF trial, the risk of a composite of stroke and systemic embolism was not statistically significant between warfarin and rivaroxaban users, aligning with our study findings [31]. Similarly, in the ENGAGE AF-TIMI 48 study, high-dose edoxaban users did not exhibit a significantly higher risk of stroke or systemic embolism compared to warfarin users (HR: 1.36, 95%CI: 0.88–2.10) in patients with CrCl > 95 mL/min [32].

Dabigatran, apixaban, and rivaroxaban demonstrated similar risks for clinical outcomes. Consistent with these findings, Korean nationwide data indicated that dabigatran, apixaban, and rivaroxaban were safer than warfarin in AF

patients with CrCl > 95 mL/min [28]. Additionally, Korean cohort data revealed that edoxaban was associated with a reduced risk of major bleeding and mortality during a median follow-up period of 5 months [29].

In a US *post-hoc* analysis, among patients with CrCl > 80 mL/min, stroke and bleeding risks were similar between warfarin and dabigatran users; however, the risk of first ischemic stroke was lower in dabigatran users (HR 0.84) and higher in rivaroxaban and apixaban users compared to warfarin users (HRs 1.07 and 1.35, respectively) [30]. Conversely, data from the ROCKET-AF trial showed no statistically significant difference in the risk of stroke or systemic embolism between VKA and NOAC users in patients with CrCl > 80 mL/min, aligning with our study findings. Similarly, the ENGAGE AF-TIMI 48 study found that high-dose edoxaban users did not have a significantly higher risk of stroke or systemic embolism compared to warfarin users (HR: 1.36, 95% CI: 0.88–2.10) in patients with CrCl > 95 mL/min.

Strengths and limitations

Our study has several strengths. First, using the global GLORIA-AF registry, we included a large cohort of “real life” AF patients with detailed 3-years of follow-up, and with over 70% NOAC prescription rate. Also, the registry includes patients with impaired renal function (CrCl < 30 mL/min) and with normal renal function (CrCl > 95 mL/min).




Fig. 2 Forest plot of analysis of risk of clinical end events in AF patients of different creatinine clearance by cox regression comparing NOAC vs. VKA (reference) treatment. Models were adjusted by age, sex, race (Asian /not Asian), BMI, smoking and drinking status, history of hypertension, cardiovascular disease, congestive heart failure, history of thromboembolism, chronic obstructive pulmonary disease,

peripheral artery disease, diabetes, previous bleeding, and any anti-platelet drug use. CrCl (mL/min): creatinine clearance; No., number of events; HR: hazard ratio; CI, confidence intervals; VKA, vitamin K anticoagulant; Ref., reference; NOACs, Non-vitamin K antagonist oral anticoagulants; CVD: cardiovascular death; MI: myocardial infarction; TE, thromboembolism events

However, there are limitations. First, this study is a *post-hoc* retrospective analysis with limited data to characterize the renal function before the onset of atrial fibrillation, which may have affected the risk of the observed outcomes. Second, although we extensively adjusted our results with multivariable Cox regression analyses, we did not include some important dependent factors, such as the CKD treatment, the anticoagulation regimes, and other co-medications which may lead to increased risk of major bleeding

[33]. Third, the number of patients prescribed edoxaban was limited, as well as those with a CrCl < 30 mL/min for each individual NOAC, particularly reducing the statistical power for some of our observations and comparisons. Additionally, OAC use was influenced by physician choice, patient adherence, and treatment management strategies. Therefore, our result should be interpreted with caution.

Table 3 Analysis of risk of clinical end events in AF patients of different creatinine clearance by cox regression comparing individual NOACs vs. VKA (reference) treatment

Outcomes	No.	HR (95% CI)	P	No.	HR (95% CI)	P	No.	HR (95% CI)	P	No.	HR (95% CI)	P	No.	HR (95% CI)	P	P for inter- action
	CrCl>95 mL/min				CrCl 80 to <95 mL/min				CrCl 50 to <80 mL/min				CrCl 30 to <50 mL/min			
All																
All cause death																
	296	Ref.		42	Ref.		31	Ref.		97	Ref.		81	Ref.		0.429
	206	0.69 (0.57, 0.82)	< 0.001	34	0.70 (0.44, 1.11)	0.129	22	0.67 (0.38, 1.16)	0.150	76	0.80 (0.59, 1.08)	0.041	62	0.70 (0.50, 0.99)	0.44 (0.23, 0.85)	0.015
	123	0.63 (0.51, 0.78)	< 0.001	16	0.46 (0.26, 0.82)	0.009	23	1.00 (0.58, 1.74)	>0.9	57	0.80 (0.58, 1.12)	0.200	25	0.63 (0.40, 1.00)	-	
Dabigatran																
168	0.73 (0.60, 0.88)	0.001	28	0.50 (0.31, 0.82)	0.006	18	0.71 (0.39, 1.29)	0.300	62	0.81 (0.59, 1.12)	0.200	52	1.00 (0.70, 1.43)	0.86 (0.38, 1.93)	0.700	
Rivaroxaban																
Composite outcomes																
	439	Ref.		72	Ref.		48	Ref.		160	Ref.		108	Ref.		0.387
	354	0.79 (0.68, 0.91)	< 0.001	63	0.73 (0.51, 1.03)	0.073	42	0.82 (0.54, 1.25)	0.400	143	0.90 (0.71, 1.13)	0.054	87	0.75 (0.56, 1.00)	0.63 (0.36, 1.10)	0.100
	215	0.70 (0.60, 0.83)	< 0.001	42	0.7 (0.47, 1.02)	0.065	33	0.82 (0.53, 1.29)	0.400	100	0.81 (0.63, 1.05)	0.110	38	0.72 (0.49, 1.06)	-	
Dabigatran																
293	0.82 (0.71, 0.95)	0.010	56	0.61 (0.43, 0.87)	0.006	40	0.97 (0.63, 1.48)	0.900	118	0.91 (0.71, 1.16)	0.400	70	1.00 (0.74, 1.36)	0.78 (0.36, 1.69)	0.500	
Rivaroxaban																
Cardiovascu- lar death																
	130	Ref.		12	Ref.		17	Ref.		37	Ref.		38	Ref.		0.411
	84	0.67 (0.51, 0.89)	0.006	15	1.08 (0.49, 2.37)	0.846	10	0.59 (0.27, 1.32)	0.200	27	0.74 (0.44, 1.23)	0.200	28	0.73 (0.44, 1.20)	0.31 (0.10, 0.91)	0.034
	54	0.66 (0.48, 0.91)	0.012	6	0.66 (0.25, 1.79)	0.418	8	0.63 (0.27, 1.50)	0.300	24	0.98 (0.58, 1.66)	>0.9	15	0.91 (0.49, 1.69)	-	
Dabigatran																
78	0.79 (0.60, 1.06)	0.112	12	0.74 (0.33, 1.69)	0.480	9	0.74 (0.32, 1.70)	0.500	27	0.91 (0.55, 1.51)	0.700	24	1.01 (0.60, 1.70)	0.91 (0.33, 2.46)	0.800	
Rivaroxaban																
Major bleeding																
	145	Ref.		31	Ref.		14	Ref.		55	Ref.		33	Ref.		0.196
	107	0.71 (0.55, 0.91)	0.008	19	0.48 (0.27, 0.86)	0.014	15	1.05 (0.50, 2.20)	0.900	50	0.87 (0.59, 1.29)	0.500	16	0.48 (0.26, 0.90)	1.20 (0.45, 3.20)	0.700
	58	0.57 (0.42, 0.77)	< 0.001	15	0.55 (0.30, 1.03)	0.060	9	0.71 (0.30, 1.67)	0.400	27	0.65 (0.41, 1.03)	0.065	7	0.48 (0.21, 1.09)	-	
Dabigatran																

Table 3 (continued)

Outcomes	No.	HR (95% CI)	P	No.	HR (95% CI)	P	No.	HR (95% CI)	P	No.	HR (95% CI)	P	No.	HR (95% CI)	P	No.	HR (95% CI)	P	P for inter- action
All				CrCl>95 mL/min			CrCl 80 to <95 mL/min			CrCl 50 to <80 mL/min			CrCl 30 to <50 mL/min			CrCl<30 mL/min			
Rivaroxaban	113	0.91 (0.71, 1.17)	0.475	23	0.57 (0.33, 0.99)	0.047	20	1.70 (0.84, 3.43)	0.140	44	0.94 (0.63, 1.40)	0.800	22	1.07 (0.61, 1.85)	0.800	4	1.21 (0.33, 4.46)	0.800	
MI																			
VKA	53	Ref.		10	Ref.		5	Ref.		19	Ref.		15	Ref.		4	Ref.		0.757
Apixaban	66	1.16 (0.80, 1.67)	0.434	12	1.04 (0.44, 2.47)	0.929	7	1.2 (0.37, 3.90)	0.800	27	1.33 (0.73, 2.42)	0.400	16	0.94 (0.45, 1.95)	0.900	4	1.45 (0.22, 9.41)	0.700	
Dabigatran	29	0.81 (0.51, 1.27)	0.358	6	0.75 (0.27, 2.11)	0.590	6	1.4 (0.42, 4.71)	0.600	12	0.90 (0.43, 1.86)	0.800	4	0.58 (0.19, 1.79)	0.300	1	-	-	
Rivaroxaban	47	1.01 (0.68, 1.50)	0.957	8	0.55 (0.21, 1.44)	0.226	6	1.33 (0.39, 4.50)	0.600	23	1.49 (0.80, 2.76)	0.200	10	0.94 (0.41, 2.15)	0.900	0	-	-	
Stroke																			
VKA	78	Ref.		15	Ref.		10	Ref.		32	Ref.		15	Ref.		6	Ref.		0.546
Apixaban	76	1.00 (0.72, 1.38)	0.997	15	0.85 (0.40, 1.80)	0.677	8	0.82 (0.31, 2.12)	0.700	37	1.24 (0.76, 2.02)	0.400	14	0.92 (0.44, 1.93)	0.800	2	0.45 (0.08, 2.70)	0.400	
Dabigatran	56	0.98 (0.69, 1.38)	0.888	13	0.99 (0.47, 2.11)	0.986	8	0.88 (0.34, 2.26)	0.800	23	0.90 (0.52, 1.54)	0.700	12	1.62 (0.75, 3.53)	0.200	0	-	-	
Rivaroxaban	54	0.89 (0.63, 1.26)	0.517	11	0.62 (0.28, 1.38)	0.242	5	0.62 (0.21, 1.85)	0.400	23	0.96 (0.56, 1.65)	0.900	12	1.22 (0.57, 2.63)	0.600	3	2.12 (0.38, 11.9)	0.400	
TE																			
VKA	81	Ref.		15	Ref.		11	Ref.		31	Ref.		16	Ref.		8	Ref.		0.550
Apixaban	90	1.07 (0.79, 1.46)	0.643	17	0.91 (0.44, 1.88)	0.81	13	1.08 (0.48, 2.47)	0.85	39	1.26 (0.78, 2.05)	0.35	17	0.95 (0.48, 1.92)	0.90	4	0.83 (0.22, 3.10)	0.786	
Dabigatran	60	1.00 (0.72, 1.41)	0.983	14	1.05 (0.50, 2.20)	0.90	7	0.62 (0.24, 1.63)	0.34	25	1.00 (0.59, 1.71)	0.99	14	1.64 (0.78, 3.44)	0.19	0	-	0.999	
Rivaroxaban	62	0.96 (0.69, 1.35)	0.831	11	0.62 (0.28, 1.36)	0.23	8	0.88 (0.35, 2.23)	0.79	29	1.22 (0.73, 2.04)	0.45	12	1.14 (0.53, 2.43)	0.74	2	0.94 (0.15, 5.92)	0.948	

Models were adjusted by age, sex, race (Asian /not Asian), BMI, smoking and drinking status, history of hypertension, cardiovascular disease, congestive heart failure, history of thromboembolism, chronic obstructive pulmonary disease, peripheral artery disease, diabetes, previous bleeding, and any antiplatelet drug use

HR, hazard ratio; CI, confidence intervals; No., number of events; CrCl, creatinine clearance; MI, myocardial infarction; TE, thromboembolism; BMI, body mass index; VKA, vitamin K anticoagulant; Ref., reference;

Conclusion

In this large prospective global registry, NOAC prescription was associated with better outcomes than VKA, regardless of renal function. These findings highlight the importance of considering renal function when choosing OAC and demonstrate the advantages of NOACs across different renal profiles. It may be advisable for clinicians to prioritize NOACs over VKAs, particularly in patients with impaired renal function or CrCl outside the 30–95 mL/min range, where the benefits were most significant.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s11239-025-03067-5>.

Acknowledgements This publication is based on research using data from data contributor Boehringer Ingelheim that have been made available through Vivli, Inc. Vivli has not contributed to or approved, and is not in any way responsible for, the contents of this publication.

Author contributions Each author has substantial contributions to the conception. YL, SLTH and GYHL designed the study. YL analysed data and wrote draft with SLTH who contributed to interpretation of data. BH, YC, TFC, BO, KH, MVH contributed to substantive revision. All authors read and approved the final manuscript. GYHL is the guarantor of this paper.

Funding This study was funded by Boehringer Ingelheim GmbH. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the manuscript, and its final contents.

Declarations

Ethical approval All patients provided written informed consent. The study protocol was approved by local institutional review boards at each participating centre. The study was conducted according to the Good Clinical Practice and the Declaration of Helsinki.

Competing interests The Authors declares that there is no financial or non-financial interests that are directly or indirectly related to the work submitted for publication.

Disclosures YL was an honorary associate research fellow at the University of Liverpool and was funded by Professor Kui Hong's national key research and development project in the Second Hospital of Nanchang University and Nanchang University Abroad Scholarship. GFR reports consultancy for Boehringer Ingelheim and an educational grant from Anthos. TFC reports honoraria for lectures from Boehringer Ingelheim, Bayer, Pfizer, and Daiichi Sankyo, outside the submitted work. MVH reports receiving research grants from the Dutch Healthcare Fund, Dutch Heart Foundation, BMS-Pfizer, Bayer Healthcare and Boehringer Ingelheim and consulting fees from BMS-Pfizer, Bayer Healthcare and Boehringer Ingelheim to the institution. GYHL is the consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, and Anthos. No fees are received personally. He is a National Institute for Health and Care Research (NIHR) Senior Investigator and co-PI of the AFFIRMO project on multimorbidity in AF (grant agreement No 899871), TARGET project on digital twins for personalised management of atrial fibrillation and stroke (grant

agreement No 101136244) and ARISTOTELES project on artificial intelligence for management of chronic long term conditions (grant agreement No 101080189), which are all funded by the EU's Horizon Europe Research & Innovation programme. Other authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Camacho EM, Lip GYH (2024) Estimating the impact of implementing an integrated care management approach with atrial fibrillation Better Care (ABC) pathway for patients with atrial fibrillation in England from 2020 to 2040. *Eur Heart J Qual Care Clin Outcomes* 10(4):326–333. <https://doi.org/10.1093/ehjqcco/qcad055>
2. Chao TF, Potpara TS, Lip GYH (2024) Atrial fibrillation: stroke prevention. *Lancet Reg Health Eur*. <https://doi.org/10.1016/j.lanepe.2023.100797>
3. Joglar JA, Chung MK, Armbruster AL et al (2024) 2023 ACC/AHA/ACCP/HRS Guideline for the diagnosis and management of Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice guidelines. *Circulation* 149(1):e1–e156. <https://doi.org/10.1161/CIR.0000000000001193>
4. Van Gelder IC, Rienstra M, Bunting KV et al (2024) 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 45(36):3314–3414. <https://doi.org/10.1093/eurheartj/ehae176>
5. Steffel J, Collins R, Antz M et al (2021) 2021 European Heart Rhythm Association practical guide on the Use of Non-vitamin K antagonist oral anticoagulants in patients with Atrial Fibrillation. *Europace* 23(10):1612–1676. <https://doi.org/10.1093/europace/euab065>
6. Stefil M, Nabrdalik K, Lip GYH (2021) Renal Disease and Atrial Fibrillation. *Card Electrophysiol Clin* 13(1):95–112. <https://doi.org/10.1016/j.ccep.2020.11.001>
7. Becattini C, Giustozzi M, Ranalli MG et al (2018) Variation of renal function over time is associated with major bleeding in patients treated with direct oral anticoagulants for atrial fibrillation. *J Thromb Haemost* 16(5):833–841. <https://doi.org/10.1111/jth.13985>
8. Emanuel S, Kaba RA, Delanerolle G et al (2023) Correct dosing, adherence and persistence of DOACs in atrial fibrillation and chronic kidney disease: a systematic review and meta-analysis. *Open Heart* 10(2). <https://doi.org/10.1136/openhrt-2023-002340>
9. Huisman MV, Teutsch C, Lu S et al (2022) Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry. *Clin Res Cardiol* 111(5):548–559. <https://doi.org/10.1007/s00392-021-01957-1>

10. Huisman MV, Lip GY, Diener HC et al (2014) Design and rationale of Global Registry on long-term oral antithrombotic treatment in patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. *Am Heart J* 167(3):329–334. <https://doi.org/10.1016/j.ahj.2013.12.006>
11. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. *Nephron* 16(1):31–41. <https://doi.org/10.1159/000180580>
12. Ding WY, Fawzy AM, Romiti GF et al (2024) Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry. *J Thromb Thrombolysis* 57(1):39–49. <https://doi.org/10.1007/s11239-023-02866-y>
13. Lip GYH, Kotalezyk A, Teutsch C et al (2022) Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry. *Clin Res Cardiol* 111(5):560–573. <https://doi.org/10.1007/s00392-022-01996-2>
14. Herndon JE 2nd, Harrell FE Jr (1995) The restricted cubic spline as baseline hazard in the proportional hazards model with step function time-dependent covariables. *Stat Med* 14(19):2119–2129. <https://doi.org/10.1002/sim.4780141906>
15. Romiti GF, Corica B, Proietti M et al (2023) Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry. *EClinicalMedicine* 63:102039. <https://doi.org/10.1016/j.eclinm.2023.102039>
16. Chao TF, Joung B, Takahashi Y et al (2022) 2021 focused Update Consensus guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: executive Summary. *Thromb Haemost* 122(1):20–47. <https://doi.org/10.1055/s-0041-1739411>
17. Ding WY, Potpara TS, Blomstrom-Lundqvist C et al (2022) Impact of renal impairment on atrial fibrillation: ESC-EHRA EORP-AF Long-Term General Registry. *Eur J Clin Invest* 52(6):e13745. <https://doi.org/10.1111/eci.13745>
18. Piccini JP, Stevens SR, Chang Y et al (2013) Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and risk factors in atrial fibrillation) study cohorts. *Circulation* 127(2):224–232. <https://doi.org/10.1161/CIRCULATIONAHA.112.107128>
19. Lau YC, Proietti M, Guiducci E, et al. Atrial fibrillation and thromboembolism in patients with chronic kidney disease. *J Am Coll Cardiol* 2016;68(13):1452–1464. <https://www.ncbi.nlm.nih.gov/pubmed/27659468>
20. Grymonprez M, Petrovic M, De Backer TL et al (2024) The impact of polypharmacy on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with Atrial Fibrillation. *Thromb Haemost* 124(2):135–148. <https://doi.org/10.1055/s-0043-1769735>
21. Romiti GF, Proietti M, Corica B et al (2023) Implications of clinical risk phenotypes on the management and natural history of Atrial Fibrillation: a Report from the GLORIA-AF. *J Am Heart Assoc* 12(20):e030565. <https://doi.org/10.1161/JAHA.123.030565>
22. Hohnloser SH, Hijazi Z, Thomas L et al (2012) Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. *Eur Heart J* 33(22):2821–2830. <https://doi.org/10.1093/eurheartj/ehs274>
23. Washam JB, Holmes DN, Thomas LE et al (2018) Pharmacotherapy for Atrial Fibrillation in patients with chronic kidney disease: insights from ORBIT-AF. *J Am Heart Assoc* 7(18):e008928. <https://doi.org/10.1161/JAHA.118.008928>
24. Coccheri S, Orlando D (2013) New oral anticoagulants in atrial fibrillation: a reappraisal of trial results looking at absolute figures. *Intern Emerg Med* 8(2):115–122. <https://doi.org/10.1007/s11739-012-0886-6>
25. Chan KE, Giugliano RP, Patel MR et al (2016) Nonvitamin K Anticoagulant agents in patients with Advanced chronic kidney disease or on Dialysis with AF. *J Am Coll Cardiol* 67(24):2888–2899. <https://doi.org/10.1016/j.jacc.2016.02.082>
26. Nielsen PB, Lane DA, Rasmussen LH et al (2015) Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. *Clin Res Cardiol* 104(5):418–429. <https://doi.org/10.1007/s00392-014-0797-9>
27. Pastori D, Ettorre E, Lip GYH et al (2020) Association of different oral anticoagulants use with renal function worsening in patients with atrial fibrillation: a multicentre cohort study. *Br J Clin Pharmacol* 86(12):2455–2463. <https://doi.org/10.1111/bcp.14350>
28. Lee SR, Choi EK, Han KD et al (2019) Non-vitamin K antagonist oral anticoagulants in Asian patients with supranormal renal function. *Stroke* 50(6):1480–1489. <https://doi.org/10.1161/STROKEAHA.118.024264>
29. Yu HT, Yang PS, Kim TH et al (2018) Impact of renal function on outcomes with Edoxaban in Real-World patients with Atrial Fibrillation. *Stroke* 49(10):2421–2429. <https://doi.org/10.1161/STROKEAHA.118.021387>
30. Fanikos J, Burnett AE, Mahan CE et al (2017) Renal function considerations for Stroke Prevention in Atrial Fibrillation. *Am J Med* 130(9):1015–1023. <https://doi.org/10.1016/j.amjmed.2017.04.015>
31. Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med* 365(10):883–891. <https://doi.org/10.1056/NEJMoa1009638>
32. Bohula EA, Giugliano RP, Ruff CT et al (2016) Impact of renal function on outcomes with Edoxaban in the ENGAGE AF-TIMI 48 Trial. *Circulation* 134(1):24–36. <https://doi.org/10.1161/CIRCULATIONAHA.116.022361>
33. Chang SH, Chou IJ, Yeh YH et al (2017) Association between Use of Non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in Nonvalvular Atrial Fibrillation. *JAMA* 318(13):1250–1259. <https://doi.org/10.1001/jama.2017.13883>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.